1628810-35-4

Basic information

• Product Name: (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride
• Synonyms: (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride
• CAS NO: 1628810-35-4
• Molecular Formula: C8H12BrClN2
• Molecular Weight: 251.55128
• Mol File: 1628810-35-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride(1628810-35-4)
• EPA Substance Registry System: (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride(1628810-35-4)

Safety Data

• Hazardous Substances Data: 1628810-35-4(Hazardous Substances Data)

Usage

Description

(S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride is an organic compound with a specific molecular structure that features a 5-bromo-4-methylpyridin-2-yl group attached to an ethanamine moiety. (S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride is characterized by its hydrochloride salt form, which contributes to its stability and solubility in various solvents. It is a key intermediate in the synthesis of biologically active molecules and has potential applications in the pharmaceutical industry due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
(S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride is used as a key intermediate in the synthesis of 3-pyrimidin-4-yl-oxazolidin-2-ones. These compounds serve as mutant IDH protein inhibitors, which are crucial in the treatment of diseases or disorders associated with mutant IDH proteins.
Used in Cancer Treatment:
(S)-1-(5-bromo-4-methylpyridin-2-yl)ethanamine hydrochloride is used as a building block for the development of inhibitors targeting mutant IDH proteins. These inhibitors play a significant role in the treatment of cell-proliferation disorders, such as cancer. By inhibiting the activity of mutant IDH proteins, these compounds can potentially slow down or stop the progression of cancer cells, offering a new avenue for therapeutic intervention in various types of cancer.